Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Conditions: Lung Cancer Interventions: Drug: Sacituzumab Govitecan; Drug: Pembrolizumab Sponsors: Chinese University of Hong Kong Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials